Alliance One International, Inc. (AOI) Reaches $19.55 After 6.00% Down Move; Progenics Pharmaceuticals (PGNX) Sentiment Is 1.31

June 7, 2018 - By Migdalia James

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Logo

The stock of Alliance One International, Inc. (NYSE:AOI) is a huge mover today! The stock decreased 6.46% or $1.35 during the last trading session, reaching $19.55. About 147,551 shares traded. Alliance One International, Inc. (NYSE:AOI) has risen 86.85% since June 7, 2017 and is uptrending. It has outperformed by 74.28% the S&P500. Some Historical AOI News: ; 21/05/2018 – Alliance One International Announces Production Expansion Of Its Canadian Cannabis Subsidiary, Launch of New Brand; 22/04/2018 DJ Alliance One International Inc, Inst Holders, 1Q 2018 (AOI); 21/05/2018 – ALLIANCE ONE INTERNATIONAL INC – SALES TO MEDICAL PATIENTS IN CANADA WILL REMAIN UNDER CURRENT BRANDING OF CANADA’S ISLAND GARDEN; 03/05/2018 – Alliance One International Announces New Executive Vice President, Global Specialty Products; 21/05/2018 – ALLIANCE ONE INTERNATIONAL INC – PHASE 1 OF EXPANSION IS A $27 MLN INVESTMENTThe move comes after 6 months negative chart setup for the $176.12 million company. It was reported on Jun, 7 by Barchart.com. We have $18.38 PT which if reached, will make NYSE:AOI worth $10.57 million less.




Progenics Pharmaceuticals Inc (PGNX) investors sentiment increased to 1.31 in Q1 2018. It’s up 0.09, from 1.22 in 2017Q4. The ratio is positive, as 68 funds increased or started new holdings, while 52 sold and decreased stock positions in Progenics Pharmaceuticals Inc. The funds in our database now own: 59.46 million shares, up from 56.89 million shares in 2017Q4. Also, the number of funds holding Progenics Pharmaceuticals Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 18 Reduced: 34 Increased: 48 New Position: 20.

More news for Alliance One International, Inc. (NYSE:AOI) were recently published by: Nasdaq.com, which released: “Marijuana ETFs Are the Smart Way to Play Canada’s Cannabis Market” on June 06, 2018. Investorplace.com‘s article titled: “Top 20 Vice Stocks for ‘Sinful’ Gains” and published on June 05, 2018 is yet another important article.

Alliance One International, Inc. purchases, processes, packs, stores, and ships leaf tobacco for manufacturers of cigarettes and other consumer tobacco products worldwide. The company has market cap of $176.12 million. It operates through North America and Other Regions divisions. It has a 3.11 P/E ratio. The firm is involved in processing and selling flue-cured, burley, and oriental tobaccos that are used in international brand cigarettes.

The stock increased 0.08% or $0.007 during the last trading session, reaching $8.847. About 452,546 shares traded. Progenics Pharmaceuticals, Inc. (PGNX) has risen 11.08% since June 7, 2017 and is uptrending. It has underperformed by 1.49% the S&P500. Some Historical PGNX News: ; 09/05/2018 – Progenics Pharmaceuticals 1Q Loss/Shr 19c; 11/05/2018 – Progenics: Plaintiffs and Par Agree That 30-Month Stay Imposed by FDA Should Be Terminated; 19/03/2018 – Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endoc; 22/03/2018 – Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131); 19/03/2018 – PROGENICS STUDY OF AZEDRA ACHIEVED PRIMARY, SECONDARY ENDPOINTS; 08/03/2018 Progenics Pharmaceuticals 4Q Loss/Shr 4c; 22/05/2018 – Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform; 22/03/2018 – Progenics Pharmaceuticals Announces Three-Mo Extension of PDUFA Date for AZEDRA(R) (iobenguane I 131); 09/05/2018 – Progenics Pharmaceuticals 1Q-End Cash and Cash Equivalents $83.4M; 19/03/2018 – Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane l 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting

More news for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) were recently published by: Globenewswire.com, which released: “Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform” on May 22, 2018. Nasdaq.com‘s article titled: “Progenics Pharmaceuticals Announces Presentation of Updated Data from the Pivotal Trial of AZEDRA® (iobenguane I …” and published on June 04, 2018 is yet another important article.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $652.23 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

Ardsley Advisory Partners holds 2.38% of its portfolio in Progenics Pharmaceuticals, Inc. for 2.13 million shares. Armistice Capital Llc owns 2.40 million shares or 1.37% of their US portfolio. Moreover, Phocas Financial Corp. has 1.18% invested in the company for 1.78 million shares. The California-based Rice Hall James & Associates Llc has invested 0.4% in the stock. Pinnacle Associates Ltd, a New York-based fund reported 2.10 million shares.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on August, 8. They expect $-0.18 earnings per share, up 25.00% or $0.06 from last year’s $-0.24 per share. After $-0.19 actual earnings per share reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.26% EPS growth.

Ratings analysis reveals 100% of Progenics Pharm’s analysts are positive. Out of 2 Wall Street analysts rating Progenics Pharm, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. PGNX was included in 2 notes of analysts from October 27, 2016. As per Monday, February 6, the company rating was upgraded by Needham. On Thursday, October 27 the stock rating was initiated by Aegis Capital with “Buy”.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.